title: EEG abnormalities during treatment with tadalafil, a phosphodiesterase type 5 inhibitor.
abstract: OBJECTIVE
  Tadalafil is a selective phosphodiesterase type 5 (PDE-5) inhibitor approved for the treatment of erectile dysfunction. Less is known about the electroencephalography (EEG) effects of PDE-5 inhibitors, and the present study, therefore, examined the risk of EEG abnormalities associated with tadalafil.
  
  
  METHODS
  EEG recordings from 35 erectile dysfunction patients taking tadalafil (20 mg) were graded for severity of EEG abnormalities (at admission, 2 and 48 hours after tadalafil administration).
  
  
  RESULTS
  At admission, there were no EEG abnormalities. At second EEG, abnormalities occurred in 12 (34.3%) of the 35 patients. Eight (22.9%) patients had mild and four (11.4%) patients had moderate EEG abnormalities. At third EEG, one (2.9%) patient had mild and one (2.9%) patient had moderate EEG abnormalities.
  
  
  CONCLUSIONS
  PDE-5 inhibitors may produce EEG abnormalities. Although the exact role of PDE in altering susceptibility to seizure remains unclear, epileptic seizures may occur during treatment with PDE inhibitors.
authors.affiliation: Department of Neurology, Mustafa Kemal University, Antakya, Turkey. esraokuyucu@yahoo.com
authors.forename: Esra E
authors.initials: EE
authors.lastname: Okuyucu
authors.forename: Oguz
authors.initials: O
authors.lastname: Guven
authors.forename: Taskin
authors.initials: T
authors.lastname: Duman
authors.forename: Sadik
authors.initials: S
authors.lastname: Gorur
authors.forename: Ismet M
authors.initials: IM
authors.lastname: Melek
authors.forename: Soner
authors.initials: S
authors.lastname: Akcin
authors.forename: Serkan
authors.initials: S
authors.lastname: Yilmazer
mesh_terms: D002243:Carbolines / Q000009:adverse effects* / Q000627:therapeutic use; D015331:Cohort Studies; D004569:Electroencephalography / Q000187:drug effects*; D007172:Erectile Dysfunction / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D058986:Phosphodiesterase 5 Inhibitors; D010726:Phosphodiesterase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D000068581:Tadalafil; D013997:Time Factors
chemical_list: D002243:Carbolines; D058986:Phosphodiesterase 5 Inhibitors; D010726:Phosphodiesterase Inhibitors; D000068581:Tadalafil